Advertisement
Research Article

Use of a Bacteriophage Lysin to Identify a Novel Target for Antimicrobial Development

  • Raymond Schuch mail,

    rschuch@contrafect.com

    Affiliation: Laboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University, New York, New York, United States of America

    Current address: ContraFect Corporation, Yonkers, New York, United States of America

    X
  • Adam J. Pelzek,

    Affiliation: Laboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University, New York, New York, United States of America

    X
  • Assaf Raz,

    Affiliation: Laboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University, New York, New York, United States of America

    X
  • Chad W. Euler,

    Affiliation: Laboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University, New York, New York, United States of America

    X
  • Patricia A. Ryan,

    Affiliations: Laboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University, New York, New York, United States of America, Hunter College School of Health Sciences, New York, New York, United States of America

    X
  • Benjamin Y. Winer,

    Affiliation: Laboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University, New York, New York, United States of America

    X
  • Andrew Farnsworth,

    Affiliation: Information Science Program, Cornell Lab of Ornithology, Ithaca, New York, United States of America

    X
  • Shyam S. Bhaskaran,

    Affiliation: Laboratory of Structural Microbiology, The Rockefeller University, New York, New York, United States of America

    X
  • C. Erec Stebbins,

    Affiliation: Laboratory of Structural Microbiology, The Rockefeller University, New York, New York, United States of America

    X
  • Yong Xu,

    Affiliation: Astex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), Dublin, California, United States of America

    X
  • Adrienne Clifford,

    Affiliation: Astex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), Dublin, California, United States of America

    X
  • David J. Bearss,

    Affiliation: Astex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), Dublin, California, United States of America

    Current address: Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States of America

    X
  • Hariprasad Vankayalapati,

    Affiliation: Astex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), Dublin, California, United States of America

    Current address: Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States of America

    X
  • Allan R. Goldberg,

    Affiliation: Astex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), Dublin, California, United States of America

    Current address: Avacyn Pharmaceuticals, Inc., Teaneck, New Jersey, United States of America

    X
  • Vincent A. Fischetti

    Affiliation: Laboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University, New York, New York, United States of America

    X
  • Published: April 10, 2013
  • DOI: 10.1371/journal.pone.0060754

Reader Comments (1)

Post a new comment on this article

Media Coverage of This Article

Posted by PLoS_ONE_Group on 12 Apr 2013 at 21:08 GMT

The following article represents some of the media coverage that has occurred for this paper:

Publication: Press Release
Title: “Scientists use Nature against Nature to develop an antibiotic with reduced resistance”
http://newswire.rockefell...

If you see any additional coverage of this paper in the press or blogosphere, please reply to this thread and add the link to the article.

Competing interests declared: PLOS ONE Staff

RE: Media Coverage of This Article

PLoS_ONE_Group replied to PLoS_ONE_Group on 22 Apr 2013 at 16:28 GMT

The following article represents some of the media coverage that has occurred for this paper:

Publication: Sci News
Title: “Epimerox: New Broad-Spectrum Antibiotic Developed, Kills MRSA, Anthrax | Medicine | Sci-News.com”
http://www.sci-news.com/m...

If you see any additional coverage of this paper in the press or blogosphere, please reply to this thread and add the link to the article.

Competing interests declared: PLOS ONE Staff

RE: RE: Media Coverage of This Article

PLoS_ONE_Group replied to PLoS_ONE_Group on 26 Apr 2013 at 23:43 GMT

The following article represents some of the media coverage that has occurred for this paper:

Publication: Ancient Bacteria-Killing Virus Holds Evolutionary Secret Against Antibiotic Resistance
Title: “Ancient Bacteria-Killing Virus Holds Evolutionary Secret Against Antibiotic Resistance”
http://www.science20.com/...

If you see any additional coverage of this paper in the press or blogosphere, please reply to this thread and add the link to the article.

Competing interests declared: PLOS ONE Staff

RE: RE: RE: Media Coverage of This Article

PLoS_ONE_Group replied to PLoS_ONE_Group on 17 May 2013 at 22:53 GMT

The following article represents some of the media coverage that has occurred for this paper:

Publication: EveryONE PLOS ONE Community Blog
Title: “PLOS ONE Goes to the Mile-High City for ASM 2013 | EveryONE”
http://blogs.plos.org/eve...

If you see any additional coverage of this paper in the press or blogosphere, please reply to this thread and add the link to the article.

Competing interests declared: PLOS ONE Staff

Media Coverage of This Article

PLoS_ONE_Group replied to PLoS_ONE_Group on 22 Jul 2013 at 17:50 GMT

The following article represents some of the media coverage that has occurred for this paper:

Publication: Digital Journal
Title: “Epimerox, a new antibiotic with potential?”
http://digitaljournal.com...

If you see any additional coverage of this paper in the press or blogosphere, please reply to this thread and add the link to the article.

Competing interests declared: PLOS ONE Staff